Between 16 June and 23 June, the Nasdaq Biotech Index (NBI) surged over 10%, the largest weekly growth since the market’s optimistic response to Donald Trump’s electoral triumph over Hillary Clinton on 8 November 2016. And it looks like the trigger was an industry event rather than an external clinical meeting or a game-changing regulatory breakthrough.
The performance of 162 companies are composited to provide a single figure for the NBI, one that might be presumed to represent the behavior of public
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?